PMAM
ACAD icon

Picton Mahoney Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Picton Mahoney Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,936
Closed -$32K – 960
2025
Q1 		$32K Buy
+1,936
New +$35.2K ﹤0.01% 485

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Picton Mahoney Asset Management's ACAD Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 1,936 shares — an estimated $32K sold.

Picton Mahoney Asset Management first reported a position in ACAD in Q1 2025 and held it in 1 quarter. The position peaked at $32K in Q1 2025. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

  • Picton Mahoney Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 1,936 Acadia Pharmaceuticals shares in Q2 2025, an estimated $32K.
  • Picton Mahoney Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Picton Mahoney Asset Management's Acadia Pharmaceuticals position peaked at $32K in Q1 2025.
  • 311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.